BioSpace News Archive

Nordic Nanovector ASA announces that following the decisions to discontinue the PARADIGME study for its lead asset Betalutin®, restructure the company and appoint Carnegie Investment Bank to explore strategic options three members of the Company’s Board have decided to step down.

NYU Langone Health announced the completion of the first orthopedic surgery in the United States using a completely wireless camera system.

Select Medical announced that 16 of its inpatient rehabilitation hospitals have been named to Newsweek’s 2022 list of America’s Best Physical Rehab Centers.

Celularity Inc., a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, announced that it entered into a Pre-Paid Advance Agreement with YA II PN, LTD, an affiliate of Yorkville Advisors Global, LP.

Valent BioSciences LLC, the global biorational products leader in agriculture, public health, and forestry, has announced the promotion of Salman Mir to Executive Vice President and Chief Operating Officer.

CAGE Bio Inc. and TAGCyx Biotechnologies Inc. announce the execution of a license agreement for development of TAGX-0003 for the targeted treatment of alopecia areata and vitiligo by dermatological application.

On September 13-14, 2022 the National Drowning Prevention Alliance (NDPA.org) hosted the industry’s first research summit solely dedicated to water safety and drowning prevention for children and adolescents - a critical issue and the single leading cause of death among children ages 1-4 years old.

NewHaptics, an innovative tactile display technology company, announced it has been awarded a Phase II Small Business Innovation Research (SBIR) grant funded by the U.S. National Institutes of Health (NIH).

Today, Folia Health announced the initiation of the ASCEND Study, a first-of-its-kind, at-home observational real-world evidence study in which people living with sickle cell disease (SCD) will use Folia’s innovative technology platform to track their individual changes in symptoms and treatment use.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced publication of peer-reviewed data detailing the discovery and preclinical profiling of antibodies from the Sorrento G-MAB™ library with neutralizing activity against SARS-CoV-2 in vitro and in vivo in Scientific Reports, a Nature portfolio journal.